Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Jodele, Sonata  [Clear All Filters]
2023
Odegard EA, Meeds HL, Kleiboeker SB, Ziady A, Sabulski A, Jodele S, Seif AE, Davies SM, Laskin BL, Blackard JT. BK Polyomavirus Diversity After Hematopoietic Stem Cell Transplantation. J Infect Dis. 2023.
Koo J, Ziady AG, Reynaud D, Abdullah S, Luebbering N, Kahn S, Langenberg L, Strecker L, Lake K, Dandoy CE, et al. Increased body mass index augments endothelial injury and clinical outcomes after hematopoietic stem cell transplant: Higher BMI increases endothelial injury after BMT. Transplant Cell Ther. 2023.
Wang YZM, Abdullah S, Luebbering N, Langenberg L, Duell A, Lake K, Lane A, Hils B, Silva OVázquez, Trapp M, et al. Intestinal permeability of stem cell transplant patients correlates with systemic acute phase responses and dysbiosis. Blood Adv. 2023.
Sabulski A, Abdullah S, Luebbering N, Aunins B, Castillo C, Lake K, Duell A, Strecker L, Langenberg L, Broomhead W, et al. Mechanisms of endothelial injury and transplant-associated thrombotic microangiopathy in tandem autologous hematopoietic stem cell transplant for neuroblastoma. Haematologica. 2023.
Schoettler ML, Lehmann LElaine, Kao P-C, Chen N, Jodele S, Chonat S, Williams KM, London WB, Duncan C, Dandoy CE. Pediatric Transplant Associated Thrombotic Microangiopathy Healthcare Utilization and Implications of Eculizumab Therapy. Blood Adv. 2023.
Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A, Mizuno K, Laskin BL, Freedman JLawrence, Davies SM. Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Blood. 2023.
Jodele S, Sabulski A. Reeling in complement in transplant-associated thrombotic microangiopathy: you're going to need a bigger boat. Am J Hematol. 2023.
2022
Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022.
Bender JD, Del Toro HOquendo-, Benoit J, Howell JC, Badia P, Davies SM, Grimley MS, Jodele S, Phillips C, Burns K, et al. Reduced Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplant: Gonadal Toxicity and Fertility Following Pediatric HSC. Transplant Cell Ther. 2022.
2021
Bhandari R, Aguayo-Hiraldo P, Malvar J, Cheng K, Sacapano A, Abdel-Azim H, Chi Y-Y, Wallace G, Asgharzadeh S, Jodele S, et al. Ultra-high dose vitamin D in pediatric hematopoietic stem cell transplantation: A nonrandomized controlled trial. Transplant Cell Ther. 2021.
2020
Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166-1177.
2019
Bhandari R, Orgel E, Rushing T, Malicse K, Evangelista V, Jodele S, Dandoy CE. Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit. Biol Blood Marrow Transplant. 2019.
Laskin BL, Denburg MR, Furth SL, Moatz T, Altrich M, Kleiboeker S, Lutzko C, Zhu X, Blackard JT, Jodele S, et al. The natural history of BK polyomavirus and the host immune response after stem cell transplantation. Clin Infect Dis. 2019.
2018
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018.
2016
Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, et al. A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA. A reduced intensity conditioning regimen for patients with Dyskeratosis Congenita undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, Wallace G, Teusink-Cross A, Davies SM. Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016.
2015
Paff Z, Dandoy C, Jodele S, Davies S, Hirsch R, Chima R. 412: ECHO ABNORMALITIES IN CRITICALLY ILL STEM CELL TRANSPLANT RECIPIENTS. Crit Care Med. 2015;43(12 Suppl 1):104-105.
Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, Setchell K, Holtzapfel C, Lane A, Taggart C, et al. Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2015.